![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Lists Rare Spinal Condition as Side Effect of AstraZeneca’s COVID-19 Shot
EMA Lists Rare Spinal Condition as Side Effect of AstraZeneca’s COVID-19 Shot
The European Medicines Agency (EMA) has recommended adding a warning about the risk of a rare form of spinal inflammation — transverse myelitis — to the list of adverse events associated with AstraZeneca’s COVID-19 vaccine.
The EMA’s safety committee conducted a review of globally reported cases, including those in its adverse events database, EudraVigilance, and concluded that “a causal relationship” between the shot and side effect is “at least a reasonable possibility.”
The EMA previously recommended adding transverse myelitis to the list of possible side effects linked with Johnson & Johnson’s (J&J) COVID-19 vaccine.
Upcoming Events
-
18Jul
-
21Oct